We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

10 hedge funds and large institutions have $678K invested in Evoke Pharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

25% more funds holding

Funds holding: 8 → 10 (+2)

2.94% more ownership

Funds ownership: 14.66% → 17.6% (+2.9%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

30% less capital invested

Capital invested by funds: $966K → $678K (-$287K)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$105K
2
BRF
B. Riley Financial
California
+$84.9K
3
TRCT
Tower Research Capital (TRC)
New York
+$904
4
Morgan Stanley
Morgan Stanley
New York
+$140

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$5.56K
2
NCM
Nantahala Capital Management
Connecticut
-$174

EVOK Hedge Fund Activity: Q1 2025 in Review

10 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2025, worth a combined $678K — down 30% from $966K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $105K. The largest seller was UBS Group, exiting entirely with an estimated $5.56K sold.

  • 10 institutional investors held Evoke Pharma (EVOK) as of Q1 2025, up from 8 in Q4 2024.
  • Funds reported $678K of Evoke Pharma stock for Q1 2025, down 30% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q1 2025 and 1 closed out, a net change of +2 holders.
  • The largest Evoke Pharma buyer in Q1 2025 was Citadel Advisors, an estimated $105K added.
  • The largest Evoke Pharma seller in Q1 2025 was UBS Group, an estimated $5.56K sold.

Based on aggregated 13F filings for Q1 2025.